Research
Research
◆ Drug Delivery System with Biomaterials
Drug delivery, which is the field of research on how to deliver drugs efficiently. Since every disease cannot be covered by the development of new drugs, it is just as important to how wisely we use our existing drugs and efficiently deliver them to the parts we need. Thus, drug delivery systems are now receiving as much attention from academia and industry as new drug development, and the bio- and pharmaceutical paradigm is shifting from drug substance development to drug delivery systems.
Biomaterials, which are engineered to treat, enhance, replace, or restore the body system for a medical purpose. It can be made through various materials such as metals, ceramics and polymers. By utilizing what kind of precursors, biomaterials have different characteristics. It should have biocompatibility that is not toxic and should not cause any in flammatory response in the body. Also, the biofunctionality that can perform a specific function by inserting the material is the most important factor.
From now on, we’ll use biomaterials and drug delivery approaches to invent innovative treatment methods in order to effectively and safely cure various diseases, particularly severe ones such as cancer and cardiovascular disease. To this end, we engineer/ process biomaterials and evaluate them in in vitro and in vivo settings.
◆ Cancer immunotherapy
Cancer immunotherapy represents a powerful approach to combat malignancy through systemic immune activation and immunological memory. However, severe off-target toxicities and poor tumor immunogenicity often restrict its clinical success. To overcome these limitations, our group engineers biomaterials, including functional polymeric nanocarriers and metal–organic frameworks, tailored for precision immuno-oncology. We focus on enhancing spatiotemporally controlled drug release, overcoming physical and physiological tumor barriers, and promoting systemic antitumor immune responses. Our ultimate goal is to translate biomaterial-driven immunotherapeutic platforms into safer, more potent clinical cancer treatments.
◆ Inflammatory disease
Inflammatory diseases, including inflammatory bowel disease, atopic dermatitis, and psoriasis, are characterized by persistent immune dysregulation and disruption of tissue homeostasis. Our group develops biomaterial-based therapeutic platforms to address these conditions by modulating inflammatory microenvironments and disease-associated immune responses. We engineer polymeric nanoparticles, metal–organic frameworks, and other functional nanomaterials to enable targeted drug delivery, attenuate oxidative stress, and regulate excessive inflammation.
Through the integration of drug delivery, anti-inflammatory activity, and immunomodulation, we aim to restore tissue homeostasis and develop more effective therapeutic strategies for chronic inflammatory diseases.